Sector News

Pfizer buys infectious disease biotech Amplyx

May 1, 2021
Life sciences

Pharmaceutical industry leaders are increasingly focused on infectious diseases amid the COVID-19 pandemic and growing concern over treatment-resistant superbugs. In July, a group of drugmakers including Pfizer announced they raised almost $1 billion for a partnership promising to deliver two to four new antibiotics by 2030.

Apart from vaccines, Pfizer’s anti-infective pipeline was thin before the Amplyx acquisition, with a treatment for COVID-19 in Phase 1 studies and an antibiotic in Phase 3. But the company’s head of hospital products, Angela Lukin, said Wednesday that Pfizer is “deeply committed” to its infectious disease program.

Fosmanogepix could prove to be a weapon against fungal infections because of its mechanism of action, Pfizer said. The Food and Drug Administration hasn’t approved a new class of antifungal therapies in almost 20 years. Researchers are currently studying both oral and intravenous forms of the drug, which in theory would help patients transition from the hospital to home. READ MORE

By Kristin Jensen


comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend